Optimum Investment Advisors’s Altimmune ALT Stock Holding History

Optimum Investment Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,000	Closed	-$21K	–	870
2020 Q2	$21K	Buy	+2,000	New	+$11K	0.01%	595

Other funds holding ALT

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Optimum Investment Advisors's ALT Position: Q3 2020 in Review

Optimum Investment Advisors sold out of Altimmune (ALT) in Q3 2020, closing a stake of 2,000 shares — an estimated $21K sold.

Optimum Investment Advisors first reported a position in ALT in Q2 2020 and held it in 1 quarter. The position peaked at $21K in Q2 2020. 72 funds tracked by Wall St. Rank hold ALT as of Q3 2020.

Optimum Investment Advisors reported no remaining Altimmune position as of Q3 2020 after selling out during the quarter.
Optimum Investment Advisors sold 2,000 Altimmune shares in Q3 2020, an estimated $21K.
Optimum Investment Advisors first reported a position in Altimmune in Q2 2020 and held it in 1 quarter.
Optimum Investment Advisors's Altimmune position peaked at $21K in Q2 2020.
72 funds tracked by Wall St. Rank held Altimmune as of Q3 2020.

Based on Optimum Investment Advisors's 13F filing for Q3 2020, filed 6 Oct 2020.